Michele Scrofani, Vice President
HQ Specialty Pharma, LLC
Paramus, NJ, April 15, 2014 HQ Specialty Pharma and its collaborating partner, WelGrace Research Group, have received tentative approval on its 505(b)(2) application for Esmolol Hydrochloride Premixed Injection, which references Brevibloc® Injection. The product will be available in two presentationsEsmolol Hydrochloride Premixed Injection 2500 mg/250 mL and Esmolol Hydrochloride DOUBLE STRENGTH Premixed Injection 2000 mg/100 mL in single-dose dual-port bags. Esmolol Premixed Injection will be marketed by WG Critical Care, LLC.
According to IMS, for the 12 months ending 2013, the US market for Brevibloc is approximately $43 million.
About HQ Specialty Pharma, LLC
HQ Specialty Pharma is a privately held specialty pharmaceutical company headquartered in Paramus, New Jersey. A global organization, the HQ Specialty Pharma product pipeline includes a number of innovative, proprietary treatments for human health, and products for animal health.
About WelGrace Research Group
WelGrace Research, headquartered in Lindenhurst, Illinois, is a global horticultural and pharmaceutical specialty company that develops a proprietary portfolio of innovative products for the global markets.
About WG Critical Care, LLC
WG Critical Care, LLC is a fully integrated pharmaceutical company headquartered in Paramus, New Jersey. WGCCs focus is to provide the hospital and specialty markets with a reliable supply of critical care products.
Brevibloc is a trademark of Baxter International Inc., or its subsidiaries.